Treatment of Low-Risk Basal Cell Carcinoma
- PMID: 28235442
- DOI: 10.1016/j.jid.2016.11.021
Treatment of Low-Risk Basal Cell Carcinoma
Abstract
With the continuously rising incidence and changing populations of patients with basal cell carcinoma, evidence about the different treatment modalities is mandatory. Randomized clinical trials, such as the surgery versus imiquimod for nodular superficial basal cell carcinoma trial, can provide this evidence. Patients can then be informed about all aspects of alternative treatment options so that conscious, shared decisions can be made.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
Comment on
-
Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial.J Invest Dermatol. 2017 Mar;137(3):614-619. doi: 10.1016/j.jid.2016.10.019. Epub 2016 Dec 5. J Invest Dermatol. 2017. PMID: 27932240 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
